IL274098B2 - Glp-2 analogs and peptibodies for administration before during, or after surgery - Google Patents
Glp-2 analogs and peptibodies for administration before during, or after surgeryInfo
- Publication number
- IL274098B2 IL274098B2 IL274098A IL27409820A IL274098B2 IL 274098 B2 IL274098 B2 IL 274098B2 IL 274098 A IL274098 A IL 274098A IL 27409820 A IL27409820 A IL 27409820A IL 274098 B2 IL274098 B2 IL 274098B2
- Authority
- IL
- Israel
- Prior art keywords
- glp
- receptor agonist
- use according
- patient
- surgery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762582055P | 2017-11-06 | 2017-11-06 | |
| PCT/US2018/059175 WO2019090209A1 (en) | 2017-11-06 | 2018-11-05 | Glp-2 analogs and peptibodies for administration before during, or after surgery |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL274098A IL274098A (en) | 2020-06-30 |
| IL274098B1 IL274098B1 (en) | 2024-08-01 |
| IL274098B2 true IL274098B2 (en) | 2024-12-01 |
Family
ID=66332372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL274098A IL274098B2 (en) | 2017-11-06 | 2018-11-05 | Glp-2 analogs and peptibodies for administration before during, or after surgery |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11660328B2 (enExample) |
| EP (1) | EP3706774A4 (enExample) |
| JP (2) | JP7296958B2 (enExample) |
| KR (1) | KR102825098B1 (enExample) |
| CN (1) | CN111629745A (enExample) |
| AR (1) | AR113835A1 (enExample) |
| AU (1) | AU2018360744A1 (enExample) |
| BR (1) | BR112020008936A2 (enExample) |
| CA (1) | CA3079523A1 (enExample) |
| IL (1) | IL274098B2 (enExample) |
| MX (1) | MX2020004620A (enExample) |
| TW (1) | TW201922279A (enExample) |
| WO (1) | WO2019090209A1 (enExample) |
| ZA (1) | ZA202002080B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7249492B2 (ja) * | 2017-08-22 | 2023-03-31 | タケダ ファーマシューティカルズ ユーエスエー インコーポレイテッド | Ｇｌｐ－２融合ポリペプチドならびに消化管の状態を処置および予防するための使用 |
| US20210355187A1 (en) * | 2018-10-24 | 2021-11-18 | Shire-Nps Pharmaceuticals, Inc. | Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| PH12022552277A1 (en) | 2020-02-28 | 2024-03-04 | Kallyope Inc | Gpr40 agonists |
| US20230129788A1 (en) * | 2020-03-30 | 2023-04-27 | Zealand Pharma A/S | Glp-1/glp-2 dual agonists |
| CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
| JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| WO2021263040A1 (en) * | 2020-06-26 | 2021-12-30 | Shire-Nps Pharmaceuticals, Inc. | Stable peptibody formulations |
| CN115636876A (zh) * | 2021-07-20 | 2023-01-24 | 重庆派金生物科技有限公司 | 胰高血糖素样肽-2突变体的定向化学偶联物及其应用 |
| CN117467025B (zh) * | 2023-12-28 | 2024-04-16 | 上海鼎新基因科技有限公司 | 一种抗vegf和补体双功能融合蛋白及其应用 |
| WO2025181330A1 (en) * | 2024-02-29 | 2025-09-04 | Vectivbio Ag | Dosage regimens for glucagon-like peptide 2 (glp-2) analogs |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1809318B1 (en) * | 2004-11-01 | 2013-06-12 | NPS Pharmaceuticals, Inc. | Treatment of short bowel syndrome patients with colon-in-continuity |
| US20090175795A1 (en) | 2005-07-29 | 2009-07-09 | Amprotein Corporation | Chimeric therapeutic agents |
| WO2007067828A2 (en) * | 2005-10-24 | 2007-06-14 | Centocor, Inc. | Glp-2 mimetibodies, polypeptides, compositions, methods and uses |
| JP5290177B2 (ja) * | 2006-08-31 | 2013-09-18 | セントカー・インコーポレーテツド | Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途 |
| JP2008247789A (ja) * | 2007-03-30 | 2008-10-16 | Kissei Pharmaceut Co Ltd | クローン病に伴う腸管狭窄の進展抑制用医薬組成物 |
| PT2755675T (pt) | 2011-09-12 | 2018-10-11 | Amunix Operating Inc | Composições de péptido semelhante a glucagão-2 e métodos para produzir e utilizar as mesmas |
| US9458214B2 (en) * | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
| KR101895047B1 (ko) | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
| CN104540850B (zh) | 2012-05-03 | 2018-05-18 | 西兰制药公司 | 胰高血糖素样肽2(glp-2)类似物 |
| CN106029087A (zh) * | 2013-12-20 | 2016-10-12 | 印第安纳大学研究及科技有限公司 | 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽 |
| KR101825048B1 (ko) * | 2014-12-31 | 2018-02-05 | 주식회사 제넥신 | GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도 |
-
2018
- 2018-11-05 KR KR1020207013387A patent/KR102825098B1/ko active Active
- 2018-11-05 EP EP18872377.9A patent/EP3706774A4/en active Pending
- 2018-11-05 MX MX2020004620A patent/MX2020004620A/es unknown
- 2018-11-05 CN CN201880071791.3A patent/CN111629745A/zh active Pending
- 2018-11-05 JP JP2020526107A patent/JP7296958B2/ja active Active
- 2018-11-05 AU AU2018360744A patent/AU2018360744A1/en not_active Abandoned
- 2018-11-05 WO PCT/US2018/059175 patent/WO2019090209A1/en not_active Ceased
- 2018-11-05 BR BR112020008936-2A patent/BR112020008936A2/pt unknown
- 2018-11-05 CA CA3079523A patent/CA3079523A1/en active Pending
- 2018-11-05 US US16/761,606 patent/US11660328B2/en active Active
- 2018-11-05 IL IL274098A patent/IL274098B2/en unknown
- 2018-11-06 TW TW107139266A patent/TW201922279A/zh unknown
- 2018-11-06 AR ARP180103232A patent/AR113835A1/es unknown
-
2020
- 2020-05-04 ZA ZA2020/02080A patent/ZA202002080B/en unknown
-
2023
- 2023-06-13 JP JP2023096692A patent/JP7752152B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111629745A (zh) | 2020-09-04 |
| WO2019090209A1 (en) | 2019-05-09 |
| MX2020004620A (es) | 2020-10-12 |
| EP3706774A1 (en) | 2020-09-16 |
| CA3079523A1 (en) | 2019-05-09 |
| KR102825098B1 (ko) | 2025-06-26 |
| AU2018360744A1 (en) | 2020-05-07 |
| KR20200085763A (ko) | 2020-07-15 |
| RU2020118172A (ru) | 2021-12-08 |
| US20210169986A1 (en) | 2021-06-10 |
| TW201922279A (zh) | 2019-06-16 |
| JP2023107883A (ja) | 2023-08-03 |
| JP7752152B2 (ja) | 2025-10-09 |
| IL274098B1 (en) | 2024-08-01 |
| ZA202002080B (en) | 2025-11-26 |
| US11660328B2 (en) | 2023-05-30 |
| JP7296958B2 (ja) | 2023-06-23 |
| BR112020008936A2 (pt) | 2020-10-20 |
| EP3706774A4 (en) | 2021-09-08 |
| JP2021502389A (ja) | 2021-01-28 |
| IL274098A (en) | 2020-06-30 |
| AR113835A1 (es) | 2020-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274098B2 (en) | Glp-2 analogs and peptibodies for administration before during, or after surgery | |
| Grounds | Reasons for the degeneration of ageing skeletal muscle: a central role for IGF-1 signalling | |
| Wakabayashi et al. | Comprehensive approach to sarcopenia treatment | |
| Raffo et al. | A pulse rapamycin therapy for infantile spasms and associated cognitive decline | |
| IL307966A (en) | Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug | |
| JP2023107883A5 (enExample) | ||
| JP2021502389A5 (enExample) | ||
| RU2015101826A (ru) | Применение долгодействующих пептидов glp-1 | |
| JP2016516016A5 (enExample) | ||
| FI3518932T3 (fi) | Eturauhassyövän hoito | |
| BR112020006246A2 (pt) | Método para controle do peso de um sujeito em necessidade | |
| JP2019530648A5 (enExample) | ||
| CA3218880A1 (en) | Methods and compositions for inducing brown adipogenesis | |
| FI3352735T3 (fi) | Pitkitetysti vapauttavia olantsapiiniformulaatioita | |
| Lang et al. | Lithium neurotoxicity: the development of irreversible neurological impairment despite standard monitoring of serum lithium levels | |
| JP5745526B2 (ja) | 糖尿病の予防のためのスルホンアミド | |
| US20240307404A1 (en) | Composition for Treatment of Muscular Disorders | |
| Sprenger et al. | 068 Evaluation of the long-term treatment effect of teriflunomide on cognitive outcomes and association with brain volume change: data from temso and its extension study | |
| Stančík et al. | Collagen type I in the treatment of painful osteoarthritis of the knee | |
| Kim et al. | The timing of intra-coronary infusion of G-CSF mobilized peripheral blood stem cells influences cardiac function and in-stent restenosis in patients with myocardial infarction | |
| Kang et al. | Comparison of the efficacy of subacromial injection with sodium bicarbonate versus corticosteroid in patients with chronic subacromial bursitis: a prospective, randomized and controlled study | |
| Bicknese et al. | GENDER DIFFERENCES AND OUTCOME TRENDS OVER TWO DECADES IN ACROMEGALY: A SINGLE CENTER STUDY IN 112 PATIENTS | |
| AT511582B1 (de) | Verwendung von keyhole-limpet-hämocyanin oder spaltprodukten davon | |
| JP2015231976A (ja) | 心筋炎の予防または治療剤 | |
| Newsome et al. | 069 Peginterferon beta-1a improves clinical and radiological disease outcomes in patients who are newly diagnosed with relapsing-remitting multiple sclerosis (RRMS): subgroup analysis of advance |